Novavax, Inc.

NASDAQ (USD): Novavax, Inc. (NVAX)

Last Price

14.67

Today's Change

+1.66 (12.79%)

Day's Change

12.68 - 14.78

Trading Volume

12,718,020

Overview

Market Cap

2 Billion

Shares Outstanding

140 Million

Avg Volume

12,932,888

Avg Price (50 Days)

5.52

Avg Price (200 Days)

5.96

PE Ratio

-4.83

EPS

-3.05

Earnings Announcement

06-Aug-2024

Previous Close

13.01

Open

12.95

Day's Range

12.68 - 14.78

Year Range

3.53 - 15.0

Trading Volume

12,827,978

Price Change Highlight

1 Day Change

13.34%

5 Day Change

11.87%

1 Month Change

271.41%

3 Month Change

257.02%

6 Month Change

158.68%

Ytd Change

193.14%

1 Year Change

95.56%

3 Year Change

-89.93%

5 Year Change

144.12%

10 Year Change

-83.28%

Max Change

-81.57%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment